Using microRNA to improve testicular cancer management
Official title: MicroRNA-371 as Markers for Disease Activity and as a Tool to Monitor the Effect of Chemotherapy and Early Detection of Recurrence in Patients With Testicular Germ Cell Tumours
Run by Haukeland University Hospital · NCT04914026 · Data updated 2026-11-12
This study is testing if a specific microRNA can help doctors better detect and manage testicular cancer by identifying active tumor cells in patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | Men only |
| Enrollment | 350 (estimated) |
| Sponsor | Haukeland University Hospital Academic / other |
| Locations | 6 sites (Bergen and 5 other locations) |
| Status | Recruiting |
| Started | December 31, 2016 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 8, 2022 |
| Trial ID | NCT04914026 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients aged 18-70 with suspected or diagnosed testicular germ cell cancer who are referred for orchiectomy.
✕Probably not a fit
Patients with other prior or concurrent malignancies or conditions that impede their ability to participate will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the performance of microRNA-371a-5p (miR371) as a biomarker for detecting viable testicular germ tumor cells in patients with testicular cancer. It will assess the sensitivity and specificity of miR371 during orchiectomy, throughout treatment, and during surveillance for early detection of recurrence. The study involves biomarker analysis to enhance the management of testicular cancer.
Why it matters
Potential benefit: If successful, this study could lead to more accurate detection and monitoring of testicular cancer, improving patient outcomes.
How similar studies have gone: Other studies have shown promise in using biomarkers for cancer detection, but the specific application of miR371 in testicular cancer is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with suspected testicular cancer, referred to orchiectomy. * Patients diagnosed with testicular germ cell cancer. * Age 18-70 years of age. * Must be able receive information and to consent. Exclusion Criteria: * Other prior or concomitant malignancy (other than testicular cancer). * Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.
Where it's running
-
Haukeland University Hospital
Bergen, Norway Recruiting -
Haugesund Hospital
Haugesund, Norway Recruiting -
University Hospital of North Norway
Tromsø, Norway Recruiting -
Karolinska University Hospital
Stockholm, Sweden Recruiting -
Oslo University Hospital
Oslo, Norway Not yet recruiting -
Sahlgrenska University Hospital
Gothenburg, Sweden Not yet recruiting
Study contacts
- Principal investigator: Mette Pernille Myklebust, PhD — Haukeland University Hospital
- Study coordinator: Mette Pernille Myklebust, PhD
- Email: mette.pernille.myklebust@helse-bergen.no
- Phone: +47 41684492
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Primary retroperitoneal lymph node surgery versus chemotherapy for good‑prognosis metastatic testicular cancer
This study will test whether primary RPLND (surgery) instead of standard chemotherapy leads to fewer side effects and better quality of life for men 18 and older with good‑prognosis metastatic testicular cancer.
-
Measuring bile acids in blood and tumor tissue to help detect and predict treatment response in testicular germ cell tumors
This project will measure bile acids and related signals in blood and tumor tissue to see if they can help detect disease and predict chemotherapy response in adult men with testicular germ cell tumors.
-
De-escalation treatments for stage II seminoma
This study is testing whether less intense treatments for stage II seminoma can help patients feel better and manage their cancer just as well as standard treatments.
-
Robot-assisted surgery for low-volume metastatic seminoma
This study is testing if robot-assisted surgery can help patients with low-volume metastatic seminoma avoid long-term side effects and improve their quality of life while also figuring out how to personalize their treatment.
-
Robot-assisted biopsy for testicular cancer
This study is testing a new robot-assisted method for taking biopsies in men with testicular cancer to see if it can more accurately find hidden cancer and reduce unnecessary treatments.
-
De-escalation treatment for early-stage seminoma
This study is testing whether giving less treatment after surgery for early-stage seminoma can still be effective while reducing side effects for patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.